ArticleCancer pathogenesis and therapy2026

Low-dose ruxolitinib as first-line therapy for acute graft-versus-host disease (aGVHD) increases the risk of Epstein-Barr virus (EBV) reactivation but not posttransplant lymphoproliferative disease (PTLD).

Kun Qian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.